# Bortezomib and Vorinostat in Treating Patients With Recurrent Mantle Cell Lymphoma or Recurrent and/or Refractory Diffuse Large B-Cell Lymphoma

> **NCT00703664** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 65 (actual)

## Conditions studied

- Recurrent Mantle Cell Lymphoma
- Recurrent Non-Hodgkin Lymphoma

## Interventions

- **DRUG:** Bortezomib
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Vorinostat

## Key facts

- **NCT ID:** NCT00703664
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-07-09
- **Primary completion:** 2017-12-01
- **Final completion:** 2017-12-01
- **Target enrollment:** 65 (ACTUAL)
- **Last updated:** 2018-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00703664

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00703664, "Bortezomib and Vorinostat in Treating Patients With Recurrent Mantle Cell Lymphoma or Recurrent and/or Refractory Diffuse Large B-Cell Lymphoma". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00703664. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*